We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biomarkers Predict Total Joint Replacements in Osteoarthritis Patients

By LabMedica International staff writers
Posted on 22 May 2019
Osteoarthritis (OA) in major joints ultimately leads to joint failure for which the only curative treatment is total joint replacement. More...
This procedure is associated with risk of complications and approximately 20% continue to experience pain.

Biomarkers may act as tools in investigating the association between biochemical and pathological processes and risk of joint failure. C-telopeptide of cross-linked collagen type I (CTX-I) and C-telopeptide of cross-linked collagen type II (CTX-II) are both considered biomarkers that may reflect disease progression in OA.

Scientists from the Krembil Research Institute (Toronto, ON, Canada) performed a post-hoc analysis, looking at data from two clinical trials that involved the use of oral supplements. They included subjects with available baseline serum CTX-I and urine CTX-II for biomarker analyses. There were a total of 27 total joint replacements (TJR), 19 knee replacements, and eight hip replacements. Investigators compared the risk of TJR of the knee or hip in patients with high versus low biomarker values using statistical analysis that controlled for age, sex, and body mass index.

The team showed that high baseline urine CTX-II was significantly associated with an elevated (3.08 times) risk of undergoing a TJR of the knee or hip during the period of study. For risk of knee replacement alone, patients with elevated CTX-I had an 8.94 times elevated risk. Elevated baseline serum CTX-I was associated with a 3.4 times higher risk of undergoing knee or hip replacement. However, this biomarker did not attain statistical significance for risk of knee arthroplasty alone.

Jonathan J. Bjerre-Bastos, MD, from Nordic Bioscience (Copenhagen, Denmark), and the lead author of the study, said, “Osteoarthritis is the most common indication for total joint replacement. Total joint replacement is an expensive procedure associated with complications and a portion of patients continue to have pain after surgery.” The study was published in the April 2019 issue of the journal Osteoarthritis and Cartilage.

Related Links:
Krembil Research Institute
Nordic Bioscience


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.